LIVN
LivaNova PLC63.08
+0.02+0.03%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reinforces conservative guidance
Q&A largely reaffirmed prepared remarks without contradictions, emphasizing conservative assumptions in 2026 guidance. Cardiopulmonary growth bakes in moderated Essence price premiums and oxygenator supply constraints from third parties, yet Essence drives double-digit HLM expansion with immaterial tender shifts recaptured in Q1. Epilepsy's 5.5-6.5% outlook prudently tempers tailwinds from 48% Medicare reimbursement hikes and CORE study impact, as two-thirds of U.S. revenue stems from durable replacements. China HLM launch hits stride this year after 2025 prep. CMS coding separates VNS/epilepsy from HGNS, no risk seen. Management stayed direct on queries. No walk-backs.
Key Stats
Market Cap
3.44BP/E (TTM)
-Basic EPS (TTM)
-3.98Dividend Yield
0%Recent Filings
10-K
FY2025 results
LivaNova's FY2025 revenue climbed 10.7% to $1.39B, with Cardiopulmonary surging 14.9% to $785M on consumables and Essenz demand, while Neuromodulation grew 7.0% to $593M across regions. Segment income jumped 19.0% to $324M, yet a $366M SNIA environmental hit flipped operating income positive to a net loss; Q4 Iranian sales hit $0.1M. Debt slashed to $377M after $281M repayments, cash at $636M. Q4 accelerated Cardiopulmonary growth. Supply chain disruptions threaten quarterly momentum.
8-K
Q4 revenue up 12.1%
LivaNova posted Q4 revenue of $360.9M, up 12.1% reported and 9.5% organic, with full-year 2025 hitting $1.39B, up 10.7% organic despite $365.6M SNIA hit causing GAAP loss. Guides 2026 constant-currency revenue growth of 6.0%-7.0%, adjusted EPS $4.15-$4.25. Momentum builds. Medicare VNS reimbursement jumps ~48%; FDA nods cloud platform.
8-K
CLO Hutchinson resigns
10-Q
Q3 FY2025 results
LivaNova posted Q3 revenue of $357.8M, up 12.5% y/y, with Cardiopulmonary surging 18% to $203.2M on Essenz and consumables while Neuromodulation grew 6.9% to $149.5M. Operating income hit $54.0M, up 51.6% y/y (derived), gross margin edged to 68.4% from 69.5%. Net income of $26.8M ($0.49 diluted EPS) beat prior $33.0M despite derivative swings; YTD net loss of $273.4M (-$5.01 EPS) reflects $363.8M SNIA charge versus operating income $156.8M. Cash swelled to $646.1M after $171.9M OCF minus $48.8M capex (FCF $123.1M, derived), Term debt fell to $349.0M post-$200M repayment, $225M revolver free. Segments thriving. Ongoing 3T litigation lingers.
8-K
Q3 beats, guidance raised
LivaNova posted Q3 revenue of $357.8M, up 12.5% reported and 12.5% organic, with Cardiopulmonary surging 18.0% on Essenz sales while Neuromodulation grew 6.9%. Adjusted EPS hit $1.11, up from $0.90. Revenue jumped. Company raised 2025 guidance: organic growth to 9.5-10.5%, adjusted EPS $3.80-$3.90, free cash flow $160M-$180M.
CVRX
CVRx, Inc.
8.32+0.14
EW
Edwards Lifesciences Corporatio
85.32+1.94
IINN
Inspira Technologies Oxy B.H.N.
1.02-0.03
LUNG
Pulmonx Corporation
2.48-0.07
MDT
Medtronic plc.
97.72-0.85
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NVCR
NovoCure Limited
12.93-0.04
VMD
Viemed Healthcare, Inc.
7.26-0.11
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
VYCO
Vycor Medical, Inc.
0.16+0.00